Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I safety and tolerability study of Acarovac Quattro

Next Previous
X
Search
Trial Profile

Phase I safety and tolerability study of Acarovac Quattro

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy Allergy Therapeutics (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Mar 2018 According to an Allergy Therapeutics media release, data is expected in H1 2019.
    • 14 Feb 2017 According to an Allergy Therapeutics media release, company is planning to initiate Phase I studies (this and other trial 281897) at two different dose regimens. Both treatment regimens include a two-to-four week initial up-dosing phase but differ in the duration of the later maintenance phase. This trial is expected to last one year.
    • 14 Feb 2017 According to an Allergy Therapeutics media release, this trial has received Clinical Trial Application (CTA) approval in Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top